|
|
|
|
|
|
Sponsors and Collaborators: |
Assistance Publique - Hôpitaux de Paris Groupe Hospitalier Pitie-Salpetriere University Hospital, Bordeaux University Hospital, Limoges Henri Mondor University Hospital University Hospital, Marseille University Hospital, Lyon, France University Hospital, Basel, Switzerland |
Information provided by: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00259974 |
Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will test the safety and efficacy of rituximab in the treatment of patients with anti-MAG polyneuropathy.
Condition | Intervention | Phase |
Polyneuropathy Associated With Anti-MAG IgM Gammopathy |
Drug: Rituximab |
Phase III |
Genetics Home Reference related topics: | aceruloplasminemia |
ChemIDplus related topics: | Rituximab |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | Double-Blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy |
Estimated Enrollment: | 60 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | January 2009 |
Acting of a polyneuropathy for which there is not any treatment of reference today (see supra), a test of double-knowledge versus placebo is justified. Acting of a chronic polyneuropathy, the clinical evaluation must be led over one one year period. Acting of a sensitive polyneuropathy and the awaited benefit being the IMPROVEMENT OF the CLINICAL SIGNS, the principal criterion is a sensitive score in addition validated in chronic sensitive polyneuropathies immunodeficiency syndrome.
The patients answering the criteria of inclusion and none inclusion (see V-2) will be randomized in 2 groups: the first group will receive a perfusion IV of rituximab to the amount of 375 mg/m2 of body surface, once per week, during 4 weeks (see VII-3); the second group will receive 4 perfusions IV of placebo according to same methods'. The evaluation (see VI-1) will be carried out at the time of the randomization, then repeated in 3 months, 6 months, 9 months and 1 year.
Ages Eligible for Study: | 18 Years to 82 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jean-Marc LEGER, MD | +33(0)-1 42 16 37 73 | jean-marc.leger@psl.aphp.fr |
France | |||||
Groupe Hospitalier Pitié-Salpétrière, Consultation de Pathologie Neuromusculaire, Bâtiment Babinski | Recruiting | ||||
PARIS, France, 75015 | |||||
Contact: Jean-Marc LEGER, MD,PhD +33(0)-1 42 16 37 73 jean-marc.leger@psl.aphp.fr | |||||
Principal Investigator: Jean-Marc LEGER, MD |
Assistance Publique - Hôpitaux de Paris |
Groupe Hospitalier Pitie-Salpetriere |
University Hospital, Bordeaux |
University Hospital, Limoges |
Henri Mondor University Hospital |
University Hospital, Marseille |
University Hospital, Lyon, France |
University Hospital, Basel, Switzerland |
Principal Investigator: | Jean-Marc LEGER, MD | Assistance Publique - Hôpitaux de Paris |
Study ID Numbers: | P040409, AOM04058 |
First Received: | November 29, 2005 |
Last Updated: | March 13, 2007 |
ClinicalTrials.gov Identifier: | NCT00259974 |
Health Authority: | France: Ministry of Health |
|
|
|
|
|